Other
Immunomodulation
Immunomodulation is an intervention with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Recruiting2
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
unknown125%
recruiting250%
completed125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT07277439
recruiting
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
NCT06248957
unknown
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML
NCT02888522
completedphase_2
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
NCT01019551
Clinical Trials (4)
Showing 4 of 4 trials
NCT07277439Phase 2
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT06248957
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
NCT02888522
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML
NCT01019551Phase 2
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
All 4 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 4